PF-00299804

Phase 2Small molecule

Pfizer

PF-00299804 is one of 178 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

177

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Head and Neck Squamous Cell CarcinomaActive, not recruiting

GlioblastomaActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Oral Cavity CancerActive, not recruiting

Lung CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 2

Active, not recruiting

GlioblastomaPhase 2

Active, not recruiting

Small Cell Lung CancerPhase 1

Active, not recruiting

Oral Cavity CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

PF-00299804

Pfizer

Phase 2

4 3

Gemzar

GGynecologic Oncology Group

Preclinical

72 4

PORTRAZZA

Eli Lilly

Preclinical

8 5

Lenvima

Eisai

Preclinical

6 6

Imjudo

AstraZeneca

Preclinical

5 7

Gilotrif

Boehringer Ingelheim

Preclinical

12 8

Ofev

Boehringer Ingelheim

Preclinical

7 9

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 10

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer4 trials

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Completed· Pfizer logo

Pfizer·Phase 2·NCT00769067·188 enrolled

PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

Completed·NNCIC Clinical Trials Group·Phase 3·NCT01000025·720 enrolled

A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804

Terminated· Pfizer logo

Pfizer·Phase 1·NCT00971191·22 enrolled

Show 1 more trial

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

Completed· Pfizer logo

Pfizer·Phase 2·NCT00548093·66 enrolled

Head and Neck Squamous Cell Carcinoma2 trials

A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma

Completed·UUniversity Health Network, Toronto·N/A·NCT01484847·6 enrolled

PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma

Completed·YYonsei University·Phase 2·NCT01449201·49 enrolled

Oral Cavity Cancer1 trial

Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment

Completed·UUniversity Health Network, Toronto·Phase 1/2·NCT01116843·13 enrolled

Small Cell Lung Cancer1 trial

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

Completed· Pfizer logo

Pfizer·Phase 1·NCT01121575·70 enrolled

Head and Neck Squamous Cell Cancer1 trial

Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer

Completed· Pfizer logo

Pfizer·Phase 2·NCT00768664·69 enrolled

6 more indications

Glioblastoma1 trial

PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma

Completed·MMassachusetts General Hospital·Phase 2·NCT01112527·58 enrolled

Lung Cancer1 trial

Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer

Completed· Pfizer logo

Pfizer·Phase 2·NCT00553254·55 enrolled

Cancer1 trial

A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients

Completed· Pfizer logo

Pfizer·Phase 1·NCT00728468·16 enrolled

Advanced Malignant Solid Tumors1 trial

A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors

Completed· Pfizer logo

Pfizer·Phase 1·NCT00783328·13 enrolled

Safety and Efficacy1 trial

A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks

Completed· Pfizer logo

Pfizer·Phase 1·NCT00728390·74 enrolled

Patients With Advanced Solid Tumors1 trial

Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors

Completed· Pfizer logo

Pfizer·Phase 1·NCT00225121·121 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for PF-00299804. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PF-00299804 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PF-00299804. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Pfizer

PF-00299804

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Non-Small Cell Lung Cancer4 trials

Head and Neck Squamous Cell Carcinoma2 trials

Oral Cavity Cancer1 trial

Small Cell Lung Cancer1 trial

Head and Neck Squamous Cell Cancer1 trial

Glioblastoma1 trial

Lung Cancer1 trial

Cancer1 trial

Advanced Malignant Solid Tumors1 trial

Safety and Efficacy1 trial

Patients With Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News